Q3 2020: Strong Third Quarter

• Group net sales increase organically by 7.2%; EBITDA pre up 19.8% organically, excluding release of the provision for patent dispute with Biogen Inc.
• Life Science grows organically by 15.6%, mainly thanks to the Process Solutions business
• Mavenclad and Bavencio drive organic growth of Healthcare; recovery in the Fertility franchise
• Semiconductor Solutions business of Performance Materials grows organically by 8.0%

Outlook for fiscal 2020

• Company expects organic sales growth of 4% to 5% over the previous year and Group net sales of between € 17.1 billion and € 17.5 billion
• Organic growth of EBITDA pre over the previous year excluding provision release between 6% and 8% expected, EBITDA pre in a range between € 5.05 billion and € 5.25 billion
  

• Quarterly statement Q3/2020 (PDF)
  

Downloads for the Media

• Press Release
• Presentation for the Media
• Digital Press Kit (ZIP File)

Additional Downloads

• Presentation for Analysts (PDF)
  
• Financial Statement (XLS)
• Financial Statement (PDF)
  
• Regional Sector Sales (XLS)
• Summary (PDF)